GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (FRA:HBP0) » Definitions » 3-Year ROIIC %

Helix BioPharma (FRA:HBP0) 3-Year ROIIC % : 5.24% (As of Jul. 2024)


View and export this data going back to . Start your Free Trial

What is Helix BioPharma 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Helix BioPharma's 3-Year ROIIC % for the quarter that ended in Jul. 2024 was 5.24%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Helix BioPharma's 3-Year ROIIC % or its related term are showing as below:

FRA:HBP0's 3-Year ROIIC % is ranked better than
62.67% of 1350 companies
in the Biotechnology industry
Industry Median: -13.43 vs FRA:HBP0: 5.24

Helix BioPharma 3-Year ROIIC % Historical Data

The historical data trend for Helix BioPharma's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma 3-Year ROIIC % Chart

Helix BioPharma Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,137.66 -35.24 34.56 396.88 5.24

Helix BioPharma Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 5.24 -

Competitive Comparison of Helix BioPharma's 3-Year ROIIC %

For the Biotechnology subindustry, Helix BioPharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helix BioPharma's 3-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's 3-Year ROIIC % falls into.



Helix BioPharma 3-Year ROIIC % Calculation

Helix BioPharma's 3-Year ROIIC % for the quarter that ended in Jul. 2024 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -6.211 (Jul. 2024) - -6.166 (Jul. 2021) )/( 0.022 (Jul. 2024) - 1.402 (Jul. 2021) )
=-0.045/-1.38
=3.26%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Helix BioPharma  (FRA:HBP0) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Helix BioPharma 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Helix BioPharma Business Description

Traded in Other Exchanges
Address
40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.

Helix BioPharma Headlines

No Headlines